B cells undergo multiple checkpoints as they mature from early development, to activation, and finally formation of memory or effector cells. Each checkpoint is regulated in large part by the strength of signal transduced through the BCR. The overall BCR signal is influenced not only by Ag affinity but also by coreceptors that either enhance or inhibit Ag signaling. For example, the CD21/CD19/CD81 coreceptor complex is a positive regulator of BCR signaling (1) , whereas Fc␥RIIB is a negative regulator (2) . Coligation of CD19 and BCR reduces the amount of anti-IgM required for optimal signaling by 10ϳ100-fold (3) . Based on this last observation, it was proposed that cross-linking the CD21/CD19 coreceptor serves to lower the threshold for B cell activation (1) .
The importance of CD21 B cell coreceptor in vivo was examined directly in the hen egg lysozyme (HEL) 4 Ig transgenic model (MD4 strain) (4). Fischer et al. (5) used an adoptive transfer approach in which the survival of Cr2 ϩ/ϩ vs Cr2 Ϫ/Ϫ MD4 B cells within splenic follicles wild-type (WT) mice immunized with either high-affinity (turkey egg white (TEL)) or moderate affinity (duck egg lysozyme (DEL)) lysozyme. Both Cr2 ϩ/ϩ and Cr2
Ϫ/Ϫ
MD4 cells responded and remained in the follicles of TEL-immunized mice. However, in mice immunized with moderate affinity lysozyme, CD21/CD35 coreceptor-deficient MD4 cells failed to survive in contrast to the Cr2 ϩ/ϩ MD4 B cells (5) . The loss was Ag-specific as normal numbers of CD21/CD35-deficient B cells were identified within splenic follicles of nonimmune WT mice after transfer. These findings support the threshold hypothesis but also raised the question whether CD21/CD35-deficient B cells were eliminated or migrate away from the follicles.
Current understanding of the regulation of peripheral B cells derives in part from transgenic models in which B cells have selfreactive receptors. Anergic B cells, for example, are eliminated by CD95-dependent apoptosis upon interaction with CD4 ϩ T cells (6) . Furthermore, acute Ag receptor engagement protects naive B cells from CD95-dependent apoptosis (7) , and in the absence of threshold signaling, both naive and anergic B cells are eliminated (8, 9) , possibly in the T cell-rich inner splenic periarteriolar lymphoid sheath region (10) . CD95 levels, initially low on resting B cells, are strongly induced after CD154-CD40 interaction (7, 8, 11) . CD95 is activated by trimerization upon binding to CD95L (12) , and its trimerized cytoplasmic region interacts with an adaptor molecule, CD95-associated death domain (FADD) (13) (14) (15) . The N-terminal region (death effector domain) of FADD binds to caspase-8 (FLICE) and activates caspase-8 by self-cleavage (16 -18) . CD95 oligomerization induced by the binding of CD95 ligand thereby results in the formation of the death-inducing-signalingcomplex (DISC), including CD95, FADD, and FLICE, and transduces signals to apoptosis executioners, the caspases (19, 20) . DISC regulation of CD95-mediated apoptosis is achieved by FLIP (18, (21) (22) (23) (24) (25) (26) (27) (28) . FLIP competes with caspase-8 for FADD binding, thereby inhibiting CD95-mediated apoptosis (21, 29) . Importantly, constitutive expression of FLIP inhibits activation-induced cell death in T cells (30) and blocks CD95L-triggered apoptosis in B cell lines (31) in vitro and leads to autoimmunity in vivo (32) .
To address whether CD95 regulation is important in the response of naive B cells to moderate affinity T-dependent Ags and to determine whether coreceptor signaling is involved in protection from the death pathway, both in vivo and in vitro approaches were taken using the well-characterized MD4 transgenic model (4) . An advantage of this model is that the MD4 BCR (developed from the HyHEL-10 hybridoma) has different affinities for various forms of avian lysozyme. For example, the transgene encoded receptor binds HEL at a very high affinity (K a ϳ4.5 ϫ 10 10 M Ϫ1 ) but DEL with only moderate affinity, e.g., ϳ1 ϫ 10 7 M Ϫ1 (33) . Because of this reduced affinity, it was predicted that MD4 B cells would be more dependent on CD21/CD19/CD81 coreceptor signaling for activation when encountering DEL. Cr2
Ϫ/Ϫ MD4 mice were bred with CD95 mutant (lpr) mice (34) , and splenic B cells from these mice (or relevant control mice) were adoptively transferred into recipients previously immunized with DEL Ags. We found that CD95 deficiency was protective against elimination of Cr2 Ϫ/Ϫ MD4 B cells. To test the role of coreceptor signaling in protection against CD95-killing, Cr2 ϩ/ϩ MD4 B cells were cultured in vitro in the presence of CD154 and either high or moderate affinity lysozyme coupled to C3d (or noncoupled) and subjected to apoptosis by CD95 cross-linking. B cells exposed to lysozyme alone were more sensitive to CD95-dependent apoptosis than B cells exposed to lysozyme-C3d. Therefore, the CD21/CD19 coreceptor acts to enhance the BCR signal to provide protection from CD95-mediated elimination. In addition, the CD95-CD95L pathway is important not only in regulation of self-reactive B cells in the periphery but provides an important checkpoint to eliminate B cells receiving subthreshold signals.
Materials and Methods

Mice
Mice were housed at Harvard Medical School in a specific pathogen-free facility. C57BL/6 mice (The Jackson Laboratory) were used as recipients. MD4 HEL Ig transgenic mice (4, 35) were maintained on a C57BL/6 background, either with or without (Cr2 Ϫ/Ϫ ; Ref. 36) intact Cr2 locus. MD4 strains were also crossed to lpr/lpr mice (C57BL/6 background). Animal protocols used were reviewed and approved by the Animal Care and Use Committees at the CBR Institute for Biomedical Research and at Harvard Medical School.
Adoptive transfer protocol
Preparation of recipient mice and transfer of MD4 B cells was performed as described previously (5) . Recipient mice were normal and not irradiated. Spleens were analyzed 1, 3, and 5 days after transfer by four-color flow cytometry and by immunohistochemistry.
Flow cytometric analysis
Splenic mononuclear cells (MNCs) were isolated by density gradient centrifugation using Lympholyte M (Cedarlane Laboratories). To detect MD4 B cells, MNCs were stained with HEL-Cy5 and counterstained with FITCconjugated peanut lectin (agglutinin) (PNA) (EY Laboratories), PerCPconjugated anti-B220 (BD Pharmingen), and PE-conjugated anti-IgM a (BD Pharmingen). The allotype of MD4 BCR is IgM a , whereas all endogenous B cells from C57BL/6 mice are IgM b . An additional allotypic marker, CD45.1, was also used to differentiate donor cells from endogenous cells. To determine CD95 levels and the percentage of MD4 B cells undergoing apoptosis, MNCs were stained with IgM a -biotin, followed by streptavidin-FITC, and counterstained with 7-aminoactinomycin D (7-AAD; Molecular Probes) and PE-conjugated CD95. Alternatively, annexin V (BD Pharmingen) was used to identify apoptotic cells in some experiments. Transferred cells were identified as being HEL 
Immunohistochemical analysis of splenic sections
Spleens were harvested from recipient mice and snap-frozen in OCT compound using a 2-methylbutane/liquid N 2 bath. Cryosections (5 M) were analyzed by immunohistological staining using HEL-biotin and alkaline phosphatase streptavidin (AP; Sigma-Aldrich) and counterstained with FITC-conjugated PNA (EY Laboratories) and HRP-conjugated anti-FITC (Boehringer Mannheim).
Western blot analysis
Lysates from 2.5 ϫ 10 5 sorted Cr2 ϩ/ϩ and Cr2 Ϫ/Ϫ MD4 B cells (pooled from 3ϳ5 mice/group each experiment) were separated by 10% SDS-PAGE and transferred to nitrocellulose membrane. Membranes were blocked in 5% dry milk (Carnation)/PBS. Fifty-five-kilodalton c-FLIP and 43-kDa-processed c-FLIP L were detected by anti-FLIP Ab (Dave-2, Alexis Biochemicals). Anti-Bcl-2 Ab (Ab-2; Oncogene Research Products) detected 26-and 19-kDa molecules. For in vitro experiments, lysates from 1 ϫ 10 6 purified B cells were used. Blots were developed with substrate 5-bromo-4-chloro-3-indolyl-phosphate/NBT (Roche) after incubation with AP-conjugated, mouse-adsorbed goat anti-rat IgG (Southern Biotechnology Associates) for c-FLIP and AP-conjugated mouse and human-adsorbed goat anti-rabbit IgG (Southern Biotechnology Associates) for BCL-2. Relative band densities were quantitated by NIH image software package.
Gene expression
RNA was prepared from FACS-sorted B cells using TRIzol (Invitrogen Life Technologies). cDNA was prepared using iSCRIPT (Bio-Rad) and normalized by PCR for ␤ 2 -microglobulin expression. c-Flip L , bcl-2, and bcl-x L expression was determined by real-time PCR (Stratagene) using the following primers (forward/reverse):
Lysozyme and lysozyme-C3d 3 production and purification HEL was purchased from Sigma-Aldrich. DEL was isolated from duck egg whites as described previously (37) . Recombinant HELC3d 3 , encoding aa 1-129 of HEL fused to three copies of the human C3d region of complement component C3, was produced using infection of sf9 insect cells with rHELC3d 3 -encoding baculovirus (kindly provided by Dr. D. Fearon, Cambridge University, Cambridge, U.K.) (38, 39) . Infected sf9 insect cells were cultured using Grace's insect medium (Invitrogen Life Technologies) supplemented with antibiotics. Recombinant HELC3d 3 from baculovirus supernatants was purified by fast protein liquid chromatography (AKT FPLC; Amersham Biosciences) using an anion-exchange column (Pharmacia). Running buffer consisted of 20 mM Tris and 5 mM EDTA. Multiple column fractions were collected after elution with Tris-EDTA buffer containing 1 M NaCl. Fractions containing rHELC3d 3 were identified by 10% SDS-PAGE using GelCode (Pierce) and by Western blot analysis with polyclonal rabbit anti-HEL Ab (BioSource International). Alternatively, rHELC3d 3 was purified by affinity chromatography as described previously (39) . To rule out potential contributions of "carry-over" molecules to B cell activation, DEL and HEL were diluted in mock-infected sf9 cell supernatants, and no differences in Fas-protection were found.
Recombinant DELC3d 3 was created using megaprimer PCR-mutagenesis using the nucleotide sequence of HEL in which residues conferring affinity changes for HyHEL-10 binding (the MD4 transgene) were changed (33) . Following sequence confirmation of mutations, rDEL was then cloned to replace HEL within the rHEL-C3d 3 baculovirus vector DNA. Recombinant DEL-C3d 3 -encoding baculovirus was engineered, and clones producing recombinant protein were identified as described previously (BD Pharmingen).
Ca 2ϩ flux
Splenocytes were loaded with a 1 mM stock solution of indo-1AM (Molecular Probes) in anhydrous DMSO at a ratio of 2-5 l:2 ϫ 10 6 cells. For loading, cells were incubated 30 min at 37°C, then washed with RPMI 1640 containing 2% FCS. Cells were subsequently stained with B220-FITC (BD Pharmingen), washed, resuspended at 2 ϫ 10 6 cells/ml, and Ca 2ϩ mobilization measured using a FACSVantage cytometer with UV laser (BD Biosciences).
Apoptosis assay
Splenic B cells were purified from MD4 mice using MACS (Miltenyi Biotec). Cells were incubated with soluble rCD154-CD8 fusion protein at 37°C, followed by anti-CD8 Ab cross-linking as described previously (40) . After overnight culture, cells were treated with goat anti-mouse IgM F(abЈ) 2 , soluble DEL/HEL and rDEL-C3d 3 /rHEL-C3d 3 at 1-10,000 pM/ 1 ϫ 10 6 cells. After 48 h of culture (exposure to CD154 for 48 h, exposure to BCR ligand to 24 h), dead cells were eliminated by sedimentation on Lympholyte M, and viable cells were labeled by incubating with 0.2 mCi of sodium chromate (Amersham Biosciences) at 37°C. Labeled cells were washed and plated on 96-well round-bottom plates at 10 5 cells/ml. Anti-CD95 Ab (Jo2; BD Pharmingen) was added at 0.9 g/ml and incubated for 5 h. CD95-specific apoptosis was determined as reported previously (7). Briefly, the following calculation was used (experimental release Ϫ spontaneous release)/(total release Ϫ spontaneous release) ϫ 100, in which total release was determined by lysing cells with Triton X-100. Cell culture supernatant was stained with 7-AAD ϩ and analyzed by FACS. Alternatively, cell culture supernatant was harvested using a Harvesting Press (Skatron), and chromium release was measured in an automatic gamma counter (PerkinElmer). Negligible B cell proliferation is observed under these culture conditions (data not shown).
Results
CD21/CD35-deficient B cells are eliminated from lymphoid follicles by CD95
To test whether Cr2 Ϫ/Ϫ B cells are eliminated by CD95-mediated apoptosis in vivo, Cr2
Ϫ/Ϫ B cells lacking functional CD95 were generated by breeding of Cr2 Ϫ/Ϫ HEL Ig transgenic (MD4) mice with CD95-mutant lpr mice (on C57BL/6J genetic background) (12, 41) . B cells from these mice were used as donors in adoptive transfer experiments to focus directly on the role of CD21/CD35 in B cell coreceptor signaling independently of follicular dendritic cell expression of CD21/CD35. Lpr MD4 B cells were transferred into DEL-immunized WT recipients (immunized 7 days before B cell transfer). As controls, Cr2 (Table I) . Similar results were observed using total splenic cells from the indicated donor strains (42) . These data support the hypothesis that CD21/CD35 expression is required for resistance to CD95-mediated elimination.
Increased apoptosis and decreased c-FLIP L in CD21/C35-deficient B cells upon engagement of moderate affinity Ag
One explanation for the difference in survival is that CD95 levels may simply be down-regulated as a result of CD21/CD35 signaling. To test this possibility, Cr2
Ϫ/Ϫ and Cr2 ϩ/ϩ MD4 B cells were examined 1 day after transfer. (Fig. 3a) . Similar levels of CD95 were observed on the surface of transferred Cr2 Ϫ/Ϫ and Cr2 ϩ MD4 B cells, indicating that differential CD95 levels were not responsible for increased apoptosis of B cells lacking intact CD21/CD35 coreceptor (CD95 mean fluorescence intensity for Cr2 Fig. 3b ). To directly test whether B cells lacking CD21/CD35 were undergoing apoptosis, levels of the early apoptotic markers annexin 
MD4 B cells compared with Cr2
ϩ/ϩ MD4 B cells ( Fig. 4a ; all three experiments summarized in Fig. 4c ). Cr2 Ϫ/Ϫ MD4 B cells also had reduced levels of the proform of c-FLIP as compared with Cr2 ϩ/ϩ MD4 B cells, although these differences were not statistically significant. These data suggest that CD21/CD35 coreceptor signaling increases c-FLIP L levels and that this may occur in part by regulating processing of the proform.
The Western blots were reprobed to examine levels of BCL-2, a molecule also known to regulate apoptosis (47) (48) (49) . BCL-2 levels reportedly increase as a consequence of CD21/CD35 signaling (46, 50) . In contrast to c-FLIP levels, no significant differences were observed in BCL-2 levels between Cr2 Ϫ/Ϫ and Cr2 ϩ/ϩ MD4 B cells in three independent experiments (Fig. 4, b and d) . Therefore, these results suggest that elimination of Cr2 Ϫ/Ϫ MD4 B cells during the ongoing immune response to DEL is not due to differential levels of BCL-2.
To further test whether CD21/CD35 signaling regulates c-FLIP L levels, Cr2
Ϫ/Ϫ and Cr2 ϩ/ϩ MD4 B cells were isolated by FACS 1 and 3 days after adoptive transfer and analyzed by real-time PCR for c-Flip L , bcl-2, and bcl-x L mRNA levels (Fig. 4, d-f) . No significant differences in bcl-2 and bcl-x L mRNA were observed between Cr2
Ϫ/Ϫ and Cr2 ϩ/ϩ MD4 B cells at either 1 or 3 days posttransfer into DEL-immunized recipients (Fig. 4, e and f) . However, consistent with protein analysis presented earlier (Fig. 4, a  and c) , a 2-to 4-fold reduction in Flip L mRNA was observed in 
Cr2
Ϫ/Ϫ MD4 B cells compared with Cr2 ϩ/ϩ MD4 B cells day 1 posttransfer (Fig. 4d) In vitro stimulation with rHELC3d 3 and DELC3d [2] [3] The in vivo adoptive transfer model strongly supports a role for CD21/CD35 coreceptor signaling in modulating c-FLIP L levels. Sensitivity to CD95 apoptosis was tested further in vitro with Cr2 ϩ/ϩ MD4 B cells exposed to CD154 with or without lysozyme (HEL or DEL) or recombinant lysozyme fused to three copies of complement fragment C3d (rHEL-C3d 3 or rDEL-C3d 3 ).
To test whether signaling through CD21/CD35 is important in protecting B cells against apoptosis, MD4 B cells with an intact coreceptor were stimulated with CD154 and either lysozyme alone or lysozyme-C3d 3 . Activated B cells were subsequently subjected to CD95 cross-linking to induce apoptosis, and apoptosis was assessed by staining with 7-AAD. CD95-specific apoptosis was determined as reported previously (7). MD4 B cells cultured in the presence of CD154 alone were more sensitive to CD95-specific apoptosis than in medium alone (Fig. 5a ). Although 100 pM HEL were required for ϳ50% protection against CD95-apoptosis, the addition of increasing quantities of HEL (up to 10 nM; data not shown) did not significantly change the sensitivity to apoptosis. Comparatively, 100 pM rHEL-C3d 3 conferred nearly full protection against CD95 killing. The protection provided by rHEL-C3d 3 was also dose dependent, as 1 pM did not protect but 10 pM provided ϳ50% protection. Therefore, the presence of C3d provided additional protection against CD95-mediated apoptosis.
To determine whether the protection against CD95-mediated apoptosis correlated with increased c-FLIP L , cultured MD4 B cell lysates were analyzed by Western blot analysis and by real-time PCR before CD95 cross-linking (Fig. 5, b-d) . Consistent with previous reports, CD154 signal alone resulted in detectable levels of c-FLIP L . The levels of c-FLIP L increased with addition of higher levels of HEL. However, the levels of c-FLIP L were increased even more significantly in rHEL-C3d 3 -stimulated MD4 B cells. Densitometric scans of blots from four independent experiments consistently demonstrated that levels of c-FLIP L were approximately equivalent in MD4 B cells stimulated with 100 pM HEL and 1 pM rHEL-C3d 3 , suggesting that HEL-C3d 3 is ϳ100-fold more potent than HEL alone in up-regulating c-FLIP L (Fig. 5c) . The relative levels of c-FLIP L continued to increase with increasing amounts of rHEL-C3d 3 , indicating a dose-dependent response similar to that observed for protection against CD95-mediated apoptosis. These results were confirmed by real-time PCR (Fig. 5d) . Importantly, no differences in viable cell numbers were found following culture with CD154 alone or in combination with HEL or rHEL-C3d 3 , indicating that increases in c-FLIP L levels were not simply due to differences in numbers of MD4 B cells after culture.
The blots were re-examined for BCL-2 levels to assess whether CD21/CD35 cocross-linking up-regulated BCL-2 as previously reported for anti-IgM/anti-CD19 stimulation (50) . Despite an increase in BCL-2 mRNA as measured by real-time PCR, no consistent up-regulation was observed in BCL-2 levels following stimulation with HEL or rHEL-C3d 3 (Fig. 5, b and d) . Therefore, increased protection of apoptosis does not correlate with increased levels of BCL-2.
The results from the in vitro assay suggest that coligation of the CD21/CD35 coreceptor and BCR by rHEL-C3d 3 fusion protein enhances survival via c-FLIP and inhibition of CD95 killing. To test whether coupling of C3d 3 to DEL also enhances protection, a rDEL-C3d 3 fusion plasmid was constructed and protein expressed in sf9 cells (Table II) (33) . To test whether the rDEL-C3d 3 was a (Fig. 6, a-d) . Approximately 100 nM DEL were required to detect above background levels of intracellular Ca 2ϩ in MD4 B cells (Fig. 6, a and c) . In contrast, significant Ca 2ϩ mobilization was detected in MD4 B cells with 1 nM rDELC3d 3 (Fig. 6b) . Therefore, as predicted from earlier studies by Dempsey et al. (38) , coupling of Cd 3 to DEL greatly enhanced early activation of B cells compared with responses with DEL alone.
To determine whether signaling by rDEL-C3d 3 was initiated through CD21/CD35 coreceptor, a blocking assay was performed using 7G6, an Ab specific for the C3d binding site on CD21/CD35 (Fig. 6c) ϩ/ϩ MD4 B cells responded similarly when treated with 100 nM DEL (Fig. 6d) , suggesting that BCR signaling was equivalent. In contrast, while treatment with 1 nM rDEL-C3d 3 To determine whether C3d 3 enhances protection of MD4 cells stimulated with DEL, CD95-dependent apoptosis was measured using 51 Cr release (7). It should be noted that the 51 Cr release assay is more sensitive than 7-AAD staining because it measures endstage apoptosis. Consistent with earlier results using HEL and rHEL-C3d 3 , coupling C3d 3 to DEL conferred better protection against CD95 killing (Fig. 7) . The protection against CD95-dependent apoptosis was dose dependent, such that increasing the amount of DEL from 1 to 100 pM increased protection. By comparison, although 50% protection using 51 Cr release assay (compare 30% protection with DEL vs 60% with CD154 stimulation alone), 1 pM rDEL-C3d 3 conferred ϳ70% protection against apoptosis. Additional protection by increasing the amount of rDELC3d 3 to 100 pM was not observed. Therefore, the presence of C3d 3 conjugated to moderate affinity lysozyme increases the resistance of Cr2 ϩ/ϩ MD4 B cells to CD95-dependent apoptosis.
Discussion
In this report, we demonstrate that B cells require complement receptor CD21/CD35 to survive in splenic follicles when encountering moderate affinity protein Ags. CD95 apoptosis eliminates 
Only nonconserved amino acid residues affecting binding affinity by MD4 BCR were targeted for mutation in rDEL, with the position indicated. Amino acid sequences for rDEL were predicted from DNA sequence analysis. Epitope mapping studies from Rajpal (51) (Fig. 4) . Increased sensitivity to apoptosis occurred in Cr2 ϩ/ϩ MD4 B cells as well as following in vitro activation with both high (HEL) and moderate (DEL) affinity lysozyme alone compared with lysozyme-C3d 3 (Figs. 5 and 7), demonstrating that differential sensitivity to apoptosis is not unique to Cr2 Ϫ/Ϫ B cells. Therefore, we conclude that CD21/CD35 coreceptor signaling on B cells protects these cells from CD95-mediated elimination during activation.
The current study confirms and extends previous examination of the importance of signal strength in regulating mature B cell activation and cell death. Cognate interaction between B and T cells via CD40-CD154 interaction, a recognized early step in B cell activation in vivo (11) , sensitizes B cells to CD95-mediated apoptosis unless the BCR is engaged by Ab cross-linking or with Ags (7, 8) . Subthreshold BCR signals subject activated B cells to deletion in the outer periarteriolar lymphoid sheath (53, 54) . The role of CD21/CD35 signaling in potentiating B cell activation is well documented in vitro. For example, the combination of coengagement of CD21/CD35 with subthreshold surface Ig cross-linking induces B cell differentiation into cell cycle more readily than antiIg stimulation alone (3) and in vivo as illustrated by adoptive transfer experiments using Cr2 Ϫ/Ϫ MD4 B cells (5) . The current results suggest that the absence of donor Cr2 Ϫ/Ϫ MD4 B cells from recipient follicles is due to their active elimination by CD95-mediated apoptosis (Table I; A number of molecules that influence CD95-mediated apoptosis are described, such as CD95 (46), c-FLIP (31, 46) , FAIM (55), Bcl-2 (50, 56), Bcl-x L (49, 56 -60) , and caspase-3 (61). BCL-2 (50, 56), CD95 (46) , and c-FLIP (46) were linked previously to CD21/CD35 signaling and were therefore examined in the current study. CD21/CD35 signaling may block CD95-mediated apoptosis either by down-regulation of CD95 or CD95 pathway mediators or by up-regulation of CD95 pathway inhibitors. Our data are consistent with this regulation occurring by increased levels of c-FLIP L , a downstream inhibitor of CD95. Analysis of donor MD4 B cells sorted one day after transfer identified similar levels of surface CD95 on Cr2
Ϫ/Ϫ and Cr2 ϩ/ϩ B cells (Fig. 3b) . These data contrast with those in a recent study with human follicular B cells stimulated with anti-Ig/C3dg dextran complexes. In that study, the investigators reported significant reductions in cell surface CD95 levels after stimulation with C3d-containing dextran complexes (46) . Several factors may explain the differences with our findings. One possibility is that the downstream effects of CD21/CD35 coreceptor signaling on murine and human B cells differ. Alternatively, differences in the nature of ligands used (anti-Ig/C3d vs lysozyme-C3d) may result in different signals generated, specifically through the BCR where anti-Ig treatment is likely more efficient at cross-linking BCR than lysozyme. CD95 levels are similar following stimulation using several conditions and likely reflect equivalent early CD40 signaling.
The mechanism of CD95-resistance in our in vivo and in vitro models is similar in that, along with no significant differences observed in CD95, BCL-2, and BCL-x L levels (Figs. 3b, 4 , b, c, e, Primary splenic B cells from MD4 mice were loaded with chromium-51, then cultured with CD40 cross-linking. After subsequent addition of F(abЈ) 2 goat anti-mouse IgM at 5 g/ml, DEL (1-100 pM) or rDEL-C3d 3 (1 and 100 pM) MD4 B cells were cultured for 24 h, then subjected to CD95 cross-linking. CD95-specific apoptosis was determined as described previously (7, 9) . Shown are representative data from one of five independent experiments. and h, and 5, b-d), c-FLIP L levels are differentially up-regulated in B cells receiving signals through CD21/CD35 (Figs. 4, a, c, and d,  5, b, c, and d) Ϫ/Ϫ B cells (Fig. 4a) , suggesting that CD21/CD35-mediated signals may influence proteolytic processing of c-FLIP. In vitro studies on CD154-activated primary B cells or c-FLIP transfected B cell lines suggest 55-kDa c-FLIP is processed to 43 kDa after anti-CD95 or soluble CD95L treatment (21, 29, 45) . Preprocessed c-FLIP (55 kDa) is recruited and cleaved at the level of DISC upon CD95 ligation (29, 45) . FLIP can be up-regulated by cross-linking BCR using an in vitro culture system of primary B cells or cell lines, providing evidence that strong BCR signaling regulates c-FLIP (31, 45) . Furthermore, in B cell lines with elevated c-FLIP levels after anti-CD95 treatment, the 43-kDa c-FLIP remained stable over the stimulation period, whereas 55-kDa c-FLIP decreased rapidly (29) , suggesting increased processing of c-FLIP. The stable c-FLIP L (43 kDa) interacts predominantly with the cleavage intermediates of caspase-8 (FLICE) to exert antiapoptotic function (29) . Because c-FLIP L is the major inhibitor of FLICE, reduced levels of c-FLIP L in Cr2 Ϫ/Ϫ MD4 B cells can allow DISC signal transduction to downstream caspases without CD95-inhibitor regulation (Fig. 4) .
The signaling pathway from CD21/CD35 to c-FLIP remains unknown. Because the regulation of c-FLIP level may depend on cell cycle (62), CD21/CD35 may regulate c-FLIP by inducing B cell proliferation (3, 50, 63) . However, preliminary results using CFSE-labeled transferred MD4 B cells showed no obvious proliferation within splenic follicles (data not shown). Therefore, although C3d or Ab cross-linking with CD21/CD35 may regulate cell cycle, it does not appear to be a major mechanism during follicular checkpoints. Instead, it may be important later during germinal center responses, during which B cells differentially express c-FLIP (64, 65) and whose survival also depends, at least in part, on CD21/CD35 coreceptor signaling (5, 66) . Despite the high-affinity interaction of HEL with the BCR transgene alone (K a ϳ4.5 ϫ 10 10 M Ϫ ), HEL-C3d 3 also provides increased CD95 resistance to MD4 B cells (Fig. 4a) . Because this correlates with increased c-FLIP L levels (Fig. 4b) , it is possible that germinal center selection may be dependent on coreceptor cross-linking. However, this possibility was not addressed herein and requires more rigorous testing to determine its validity.
Covalent association of Ags with C3d, a ligand for complement receptors CD21/CD35, leads to augmented humoral responses and led to the proposal that C3d (and C3dg) is a molecular adjuvant (38, (67) (68) (69) (70) . Because of the well-documented role of CD21/CD35 as a B cell coreceptor as described above, it is speculated that Ag-C3d(g) adducts potentiate stronger immune responses in part by eliciting stronger signaling in Ag-specific B cells. A recent report by Haas et al. (71) in which Ag-C3d immunization provoked Ab responses in CD21/CD35-deficient mice suggests there may be other CD21/CD35-independent mechanisms responsible for regulating responses. Both the in vivo and in vitro approaches used in the current study isolate CD21/CD35 defects to the MD4 B cells. We specifically tested whether signaling by lysozyme-C3d conjugates was mediated through CD21/CD35 in vitro by Ca 2ϩ mobilization assay (Fig. 6 ). C3d-augmented signaling was specifically blocked by anti-CD21/CD35 Ab, and this block was ameliorated by addition of an equivalent concentration of lysozyme to cause mobilization by Ag alone (Fig. 6c) . Stimulation of Cr2 Ϫ/Ϫ MD4 B cells with 1 nM rDEL-C3d 3 failed to stimulate a significant increase in intracellular Ca 2ϩ levels relative to Cr2 ϩ/ϩ MD4 B cells, consistent with impaired coreceptor activity (Fig. 6d) . Therefore, the effects of lysozyme-C3d in regulating B cell fate are mediated through complement receptors CD21/CD35.
In summary, we found that the CD21/CD35 coreceptor is important in maintaining B cell survival following engagement of the CD95 receptor. The finding that c-FLIP levels are up-regulated following cross-linking of CD21/CD35 supports a direct role for coreceptor signaling in blocking CD95-dependent apoptosis. This regulation may represent an important mechanism by which bystander B cells are censored in the absence of coreceptor activation, thereby preventing unwanted immune responses.
